Pharmacotherapy for atrial fibrillation. The rhythm control strategy (review)

Atrial fibrillation (AF) is the most common supraventricular tachyarrhythmia and is associated with increased cardiovascular complications and mortality. The current patient management paradigm is shifting from a rate control strategy to early and proactive rhythm control, as supported by large randomized trials and current European and Russian guidelines. This review examines the pathophysiological basis of arrhythmogenesis in AF, including the levels of electrical, mechanical, structural, and autonomic atrial remodeling, as well as the key mechanisms of arrhythmia initiation and maintenance (ectopic activity, reentry, trigger activity/delayed afterdepolarizations). Particular attention is paid to the pharmacological strategy of rhythm control using following Vaughan-Williams class I and III antiarrhythmic agents: the molecular targets, pharmacokinetics, clinical efficacy, and safety profile of propafenone, flecainide, lappaconitine hydrobromide (allapinin), ethacizine, amiodarone, sotalol, and others are analyzed, including drugs primarily available in Russia. Based on current data and guidelines, an algorithmic approach to the selection of anti-relapse therapy is proposed, taking into account the patient’s phenotype (paroxysmal or persistent AF, structural myocardial pathology, heart failure coronary artery disease, left ventricular hypertrophy), the level of atrial remodeling, conduction system characteristics, comorbidities, and drug interactions. The characteristics of antiarrhythmic therapy in the early period after cardioversion and after pulmonary vein catheter isolation as part of a hybrid strategy (invasive+drug therapy) are separately discussed. This review is intended for practicing cardiologists and arrhythmologists and aims to facilitate the individualization of antiarrhythmic drug selection within the safe and effective rhythm control strategy for AF.

1. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery (EACTS). European Heart Journal. 2024;45:3314-414. doi:10.1093/eurheartj/ehae176.

2. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. doi:10.1056/NEJMoa021328.

3. Hagens VE, Van Gelder IC, Crijns HJGM, RAte Control Versus Electrical Cardioversion Of Persistent Atrial Fibrillation (RACE) Study Group. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation. Card Electrophysiol Rev. 2003;7:118-21. doi:10.1023/a:1027439430017.

4. Van Gelder IC, Hagens VE, Bosker HA, et al. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. N Engl J Med. 2002;347:1834-40. doi:10.1056/NEJMoa021375.

5. Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383:1305-16. doi:10.1056/NEJMoa2019422.

6. Eckardt L, Sehner S, Suling A, et al. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J. 2022;43:4127-44. doi:10.1093/eurheartj/ehac471.

7. Rillig A, Magnussen C, Ozga A-K, et al. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation. 2021;144:845-58. doi:10.1161/CIRCULATIONAHA.121.056323.

8. Golitsyn SP, Golukhova EZ, Mikhailov EN, et al. 2025 Clinical practice guidelines for Atrial fibrillation and flutter. Russ J Cardiol. 2025;30(11):6668. (In Russ.) doi:10.15829/1560-4071-2025-6668. EDN: MGXGON.

9. Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular Society/ Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology. 2020;36:1847-948. doi:10.1016/j.cjca.2020.09.001.

10. Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.) doi:10.15829/1728-8800-2019-1-5-66.

11. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325. doi:10.1152/physrev.00031.2009.

12. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1 e156. doi:10.1161/CIR.0000000000001193.

13. Jahangir A, Lee V, Friedman PA, et al. Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation: A 30-Year Follow-Up Study. Circulation. 2007;115:3050-6. doi:10.1161/CIRCULATIONAHA.106.644484.

14. Kato T, Yamashita T, Sagara K, et al. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14 year follow-up study. Circ J. 2004;68:568-72. doi:10.1253/circj.68.568.

15. Piña PG, Chicos AB. Early Cardioversion in Atrial Fibrillation: Earlier Is Better, but Not Always and (Maybe) Not Immediately. Curr Atheroscler Rep. 2017;19:3. doi:10.1007/s11883-017-0638-1.

16. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial Fibrillation Begets Atrial Fibrillation: A Study in Awake Chronically Instrumented Goats. Circulation. 1995;92:1954- 68. doi:10.1161/01.CIR.92.7.1954.

17. Schotten U, Neuberger H-R, Allessie MA. The role of atrial dilatation in the domestication of atrial fibrillation. Progress in Biophysics and Molecular Biology. 2003;82:151-62. doi:10.1016/S0079-6107(03)00012-9.

18. Franz MR, Karasik PL, Li C, et al. Electrical Remodeling of the Human Atrium: Similar Effects in Patients With Chronic Atrial Fibrillation and Atrial Flutter. Journal of the American College of Cardiology. 1997;30:1785-92. doi:10.1016/S0735-1097(97)00385-9.

19. Yue L, Feng J, Gaspo R, et al. Ionic Remodeling Underlying Action Potential Changes in a Canine Model of Atrial Fibrillation. Circulation Research. 1997;81:512-25. doi:10.1161/01.RES.81.4.512.

20. Sánchez J, Gomez JF, Martinez-Mateu L, et al. Heterogeneous Effects of FibroblastMyocyte Coupling in Different Regions of the Human Atria Under Conditions of Atrial Fibrillation. Front Physiol. 2019;10:847. doi:10.3389/fphys.2019.00847.

21. Casaclang-Verzosa G, Gersh BJ, Tsang TSM. Structural and Functional Remodeling of the Left Atrium. Journal of the American College of Cardiology. 2008;51:1-11. doi:10.1016/j.jacc.2007.09.026.

22. Tarasov AV, Karakiyan AA, Povarov VO. Mechanisms of atrial remodeling in patients with atrial fibrillation and their relationship with the effectiveness of different treatment methods. Pharmateca. 2024;31(9):20-8. (In Russ.) EDN: IZJTHU.

23. Thijssen VLJL, Ausma J, Liu GS, et al. Structural Changes of Atrial Myocardium During Chronic Atrial Fibrillation. Cardiovascular Pathology. 2000;9:17-28. doi:10.1016/S1054-8807(99)00038-1.

24. Waks JW, Josephson ME. Mechanisms of Atrial Fibrillation — Reentry, Rotors and Reality. Arrhythm Electrophysiol Rev. 2014;3:90-100. doi:10.15420/aer.2014.3.2.90.

25. Garrey WE. The nature of fibrillary contraction of the heart — its relation to tissue mass and form. American Journal of Physiology-Legacy Content. 1914;33:397-414. doi:10.1152/ajplegacy.1914.33.3.397.

26. Mayor AG. Rhythmical pulsation in Scyphomedusae. Washington, D.C.: Carnegie Institution of Washington, 1906. p. 86.

27. Mines GR. On dynamic equilibrium in the heart. J Physiol. 1913;46:349-83. doi:10.1113/jphysiol.1913.sp001596.

28. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J. 1959;58:59-70. doi:10.1016/0002-8703(59)90274-1.

29. Shiroshita-Takeshita A, Brundel BJJM, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol. 2005;13:181-93. doi:10.1007/s10840-005-2362-y.

30. Katra RP, Laurita KR. Cellular mechanism of calcium-mediated triggered activity in the heart. Circ Res. 2005;96:535-42. doi:10.1161/01.RES.0000159387.00749.3c.

31. Coetzee WA, Opie LH. Effects of components of ischemia and metabolic inhibition on delayed afterdepolarizations in guinea pig papillary muscle. Circ Res. 1987;61:157- 65. doi:10.1161/01.res.61.2.157.

32. Metelitsa VI. Handbook of clinical pharmacology of cardiovascular drugs. 3rd ed. Moscow: Medicine Information Agency, 2005. p. 1528. (In Russ.) ISBN: 5-89481-320-4.

33. Blagova OV. Drug treatment of cardiac arrhythmias. Sulimov VA (ed.), Moscow: GEOTARMedia, 2011. 438 p. (In Russ.) ISBN: 978-5- 9704-1823-9.

34. Tarasov AV. Safety issues of antiarrhythmic therapy. Consilium Medicum. 2014;16(10):44-9. (In Russ.) EDN: SXCNNF.

35. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-8. doi:10.1056/NEJM199103213241201.

36. Martínez-Rubio A, Tamargo J, Dan G-A, editors. Antiarrhythmic Drugs. 2nd ed. Cham: Springer Nature Switzerland AG, 2024. 521 p. ISBN: 978-3-031-74045-9.

37. Abriel H, Rougier J-S, Jalife J. Ion Channel Macromolecular Complexes in Cardiomyocytes: Roles in Sudden Cardiac Death. Circ Res. 2015;116:1971-88. doi:10.1161/CIRCRESAHA.116.305017.

38. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351:2384-91. doi:10.1056/NEJMoa041233.

39. Edrich T, Wang S-Y, Wang GK. State-dependent block of human cardiac hNav1.5 sodium channels by propafenone. J Membr Biol. 2005;207:35-43. doi:10.1007/s00232-005-0801-4.

40. Connolly SJ, Kates RE, Lebsack CS, et al. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol. 1983;52:1208-13. doi:10.1016/0002-9149(83)90575-1.

41. Hollmann M, Brode E, Hotz D, et al. Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung. 1983;33:763-70.

42. Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987;75:785-91. doi:10.1161/01.cir.75.4.785.

43. Tran QT, Baek I-H, Han N-Y, et al. The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022;14:1446. doi:10.3390/pharmaceutics14071446.

44. Valderrábano M, Singh BN. Electrophysiologic and Antiarrhythmic Effects of Propafenone: Focus on Atrial Fibrillation. J Cardiovasc Pharmacol Ther. 1999;4:183-98. doi:10.1177/107424849900400308.

45. Tsaregorodtsev DA, Okisheva EA, Gracheva EI, et al. The new approach to efficiency and safe evaluation of etacizin in patients without morfological heart pathology. Russian Journal Of Cardiology And Cardiovascular Surgery. 2014;7(2):89-96. (In Russ.)

46. Gao X, Guha A, Buck B, et al. Initiation and outcomes with Class Ic antiarrhythmic drug therapy. Indian Pacing Electrophysiol J. 2018;18:68-72. doi:10.1016/j.ipej.2017.12.001.

47. Jespersen CHB, Krøll J, Bhardwaj P, et al. Use of Nonrecommended Drugs in Patients With Brugada Syndrome: A Danish Nationwide Cohort Study. J Am Heart Assoc. 2023;12:e028424. doi:10.1161/JAHA.122.028424.

48. Holm J, Lindh JD, Andersson ML, Mannheimer B. The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. J Thromb Haemost. 2017;15:446-53. doi:10.1111/jth.13614.

49. Merino JL, Tamargo J, Blomström-Lundqvist C, et al. Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2025;27:euaf076. doi:10.1093/europace/euaf076.

50. Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol. 2015;7:76-85. doi:10.4330/wjc.v7.i2.76.

51. Crozier I. Flecainide in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1992;70:26A 32A. doi:10.1016/0002-9149(92)91074-e.

52. Hellestrand KJ, Nathan AW, Bexton RS, Camm AJ. Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds. Am J Cardiol. 1984;53:30B 38B. doi:10.1016/00029149(84)90499-5.

53. Behr ER, Winkel BG, Ensam B, et al. The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy, the Association of European Paediatric and Congenital Cardiology (AEPC), the Paediatric & Congenital Electrophysiology Society (PACES), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace. 2025;27(4):euaf067. doi:10.1093/europace/euaf067.

54. Tamargo J, Le Heuzey J-Y, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol. 2015;71:549-67. doi:10.1007/s00228-015-1832-0.

55. Lavalle C, Magnocavallo M, Straito M, et al. Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias. J Clin Med. 2021;10:1456. doi:10.3390/jcm10071456.

56. Bordier P, Garrigue S, Bernard V, et al. Flecainide-induced Increase in QRS Duration and Proarrhythmia during Exercise. Clin Drug Investig. 1997;13:326-37. doi:10.2165/00044011-199713060-00005.

57. Vallurupalli S, Pothineni NVK, Deshmukh A, Paydak H. Utility of Routine Exercise Testing to Detect Rate-Related QRS Widening in Patients Without Structural Heart Disease on Class Ic Antiarrhythmic Agents (Flecainide and Propafenone). Am J Cardiol. 2015;116:730-32. doi:10.1016/j.amjcard.2015.05.039.

58. Rivner H, Lambrakos LK. Flecainide Toxicity Leading to Loss of Pacemaker Capture and Cardiac Arrest. JACC Case Rep. 2021;3:586-90. doi:10.1016/j.jaccas.2020.11.030.

59. Mar PL, Horbal P, Chung MK, et al. Drug Interactions Affecting Antiarrhythmic Drug Use. Circ Arrhythm Electrophysiol. 2022;15:e007955. doi:10.1161/CIRCEP.121.007955.

60. Shea P, Lal R, Kim SS, Schechtman K, Ruffy R. Flecainide and amiodarone interaction. J Am Coll Cardiol. 1986;7:1127-30. doi:10.1016/s0735-1097(86)80234-0.

61. Lewis GP, Holtzman JL. Interaction of flecainide with digoxin and propranolol. Am J Cardiol. 1984;53:52B 57B. doi:10.1016/0002-9149(84)90502-2.

62. Vakhitova YuV, Farafontova EI, Khisamutdinova RYu, et al. A study of the mechanism of the antiarrhythmic action of allapinin. Bioorganicheskaya Khimiya. 2013;39(1):105. (In Russ.) doi:10.7868/S0132342313010119.

63. Sokolov SF. Results of clinical studies of allapinin and up-to-date approaches to treatment of patients with cardiac arrhythmias. Journal of Arrhythmology. 2011;(64):60-70. (In Russ.)

64. Erlikh AD. The study of evidence base for the use of lappaconitine hydrobromide in patients with atrial fibrillation. Kardiologiia. 2016;56(3):48-53. (In Russ.) doi:10.18565/cardio.2016.3.48-53.

65. Archakova OA, Bagaeva NS, Komarov TN, et al. Pharmacokinetics study of the long-acting antiarrhythmic drug of lappaconitine hydrobromide (Allaforte®, JSC "Pharmcenter VILAR", Russia). Drug Development & Registration. 2022;11(1):140-7. (In Russ.) doi:10.33380/2305-2066-2022-11-1-140-147.

66. Loginova AI, Mironov NYu, Sviridova VV, et al. Ethacizine application for suppression of ventricular extrasystole in a patients after ineffective catheter ablation. Effective Pharmacotherapy. 2025;21(19):46-50. (In Russ.). doi:10.33978/2307-3586-2025-21-19-46-50.

67. Doshchitsin VL, Tarzimanova AI. Historical aspects of the use of antiarrhythmic drugs in clinical practice. Rational Pharmacotherapy in Cardiology. 2022;18(3):350-8. (In Russ.) doi:10.20996/1819-6446-2022-06-07.

68. Tsaregorodtsev DA, Okisheva EA, Sulimov VA. The use of 1st class antiarrhythmics in modern therapy of cardiac arrhythmias. Cardiology and Cardiovascular Surgery. 2012;5(6):54-7. (In Russ.)

69. Golitsyn SP, Panchenko EP, Mironov NYu, et al. Eurasian clinical guidelines for the diagnosis and treatment of atrial fibrillation in adult patients (2025). Eurasian Heart Journal. 2025;(3):6-77. (In Russ.) doi:10.38109/2225-1685-2025-3-6-77.

70. Pavlov EG, Chapurnykh AV, Soloviev OV. Ethacyzin in combined therapy of recurrent atrial fibrillation. Cardiology and Cardiovascular Surgery. 2010;3(1):64-70. (In Russ.)

71. Sokolov SA, Bomonina EV. Comparative efficacy and safety of allapinine, ethacyzin and amiodarone: choice of optimal antiarrhythmic therapy for rhythm control in case of paroxysmal atrial fibrillation. Cardiology: News, Opinions, Training. 2015;(3):65-75. (In Russ.)

72. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125:381-9. doi:10.1161/CIRCULATIONAHA.111.019927.

73. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686-90. doi:10.1161/01.cir.81.2.686.

74. Horváth B, Hézső T, Kiss D, et al. Late Sodium Current Inhibitors as Potential Antiarrhythmic Agents. Front Pharmacol. 2020;11:413. doi:10.3389/fphar.2020.00413.

75. Șorodoc V, Indrei L, Dobroghii C, et al. Amiodarone Therapy: Updated Practical Insights. J Clin Med. 2024;13:6094. doi:10.3390/jcm13206094.

76. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-72. doi:10.1056/NEJMoa041705.

77. Van Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Health Risk Manag. 2010;6:465-72. doi:10.2147/vhrm.s6611.

78. Tisdale JE, Chung MK, Campbell KB, et al.; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142:e214 e233. doi:10.1161/CIR.0000000000000905.

79. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298:1312-22. doi:10.1001/jama.298.11.1312.

80. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991;31:1061-9. doi:10.1002/j.1552-4604.1991.tb03673.x.

81. Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician. 2003;68:2189-96.

82. Bartalena L, Bogazzi F, Chiovato L, et al. 2018 European Thyroid Association (ETA). Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018;7:55-66. doi:10.1159/000486957.

83. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16:43-8. doi:10.1155/2009/282540.

84. Carpenter M, Berry H, Pelletier AL. Clinically Relevant Drug-Drug Interactions in Primary Care. Am Fam Physician. 2019;99:558-64.

85. Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75:1341-50. doi:10.1016/j.jacc.2019.12.068.

86. Kpaeyeh JA, Wharton JM. Sotalol. Card Electrophysiol Clin. 2016;8:437-52. doi:10.1016/j.ccep.2016.02.007.

87. Anderson JL, Prystowsky EN. Sotalol: An important new antiarrhythmic. Am Heart J. 1999;137:388-409. doi:10.1016/s0002-8703(99)70484-9.

88. Antonaccio MJ, Gomoll A. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am J Cardiol. 1990;65:12A 21A; discussion 35A 36A. doi:10.1016/0002-9149(90)90196-8.

89. Biswas M, Levy A, Weber R, et al. Multicenter Analysis of Dosing Protocols for Sotalol Initiation. J Cardiovasc Pharmacol Ther. 2020;25:212-8. doi:10.1177/1074248419887710.

90. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d, l-sotalol. Circulation. 1996;94:2535-41. doi:10.1161/01.cir.94.10.2535.

91. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7-12. doi:10.1016/s0140-6736(96)02149-6.

92. McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J. 1984;51:157-62. doi:10.1136/hrt.51.2.157.

93. Tarasov AV, Davtyan KV, Miller ON. Rational antiarrhythmic therapy in postoperative period of pulmonary vein ostia catheter isolation according to the efficacy and safety, for prevention of early recurrences of atrial tachyarrhythmias. Consilium Medicum. 2017;19(1):81-7. (In Russ.) doi:10.26442/2075-1753_2017.19.1.81-87.

94. Goldenberg GR, Burd D, Lodzinski P, et al. Antiarrhythmic therapy as an adjuvant to promote post pulmonary vein isolation success-a meta-analysis. J Interv Card Electrophysiol. 2016;47:171-6. doi:10.1007/s10840-016-0157-y.